In the Western world, more than 90% of head and neck cancers are head and neck
squamous cell carcinomas (HNSCCs). The most appropriate treatment approach for …

Abstract Purpose: As Toll-like receptors (TLR) are key mediators of immune responses, TLR
agonists may be important for augmenting the efficacy of therapies for squamous cell …

Objectives A wide range of objective response rates (ORRs: 0–53%) among available
treatments in patients with R/M HNSCC with progression on or after platinum-based …

In recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M-
SCCHN), the armamentarium of systemic anti-cancer modalities continues to grow in …

ContextMalignancies arising from the aerodigestive epithelium, including lung, head and
neck, and esophageal carcinomas, are the leading causes of cancer-related mortality …

Expression of EGF receptor (EGFR) is frequently elevated in squamous cell carcinoma of the
head and neck (SCCHN). Cetuximab is an anti-EGFR monoclonal antibody that has been …

Although the prognosis of cancer remains poor recent advances in the diagnostic methods,
new approaches in surgical procedures and the development of new therapeutic agents …

The development of epidermal growth factor receptor (EGFR) inhibitors was greeted with
tremendous enthusiasm in the therapy of squamous cell carcinoma of the head and neck …

Purpose: This phase 1 study evaluated the pharmacokinetic and pharmacodynamic effects
of cetuximab on patients with epithelial malignancies. Experimental Design: Following a skin …

Head and neck cancer is the sixth most common cancer worldwide. At present, globally
about 650,000 new cases of squamous cell carcinoma of the head and neck (SCCHN) are …